Abnormal Platelet Aggregation in Patients with Bartter’s Syndrome

  • F. Fabris
  • G. Opocher
  • A. Casonato
  • M. Randi
  • A. Girolami
  • F. Mantero


Bartter’s syndrome is characterized by hypokalemia, hyperreninemia, hyperaldosteronism without hypertension, and juxtaglomerular cell hyperplasia.1 Recent studies have demonstrated an increase of the urinary excretion of prostaglandins (PGs) PGE2, PGF 2–4 and 6-keto PGF 5,6 in cases of Bartter’s syndrome.


Arachidonic Acid Platelet Aggregation Platelet Function Aggregation Defect Platelet Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bartter FC, Pronove P, Gill R, et al: Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33: 811–828, 1962.PubMedCrossRefGoogle Scholar
  2. 2.
    Ciabattoni G, Pugliese F, Spaldi M, et al: Radioimmunoassay measurement of prostaglandins E2 and F2 alpha in human urine. J Endocrinol Invest 2: 173–182, 1979.PubMedGoogle Scholar
  3. 3.
    Dillon MJ, Shah V, Mitchell MD: Bartter’s syndrome: 10 cases in childhood Q J Med 48 (191): 429–447, 1979.PubMedGoogle Scholar
  4. 4.
    Fichman MP, Telfer N, Zia P, et al: Role of prostaglandins in the pathogenesis of Bartter’s syndrome. Am J Med 60: 785–798, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Ciabattoni G, Pugliese F, Cinotti GA, et al: Ruolo della prostaciclina (PGI2) nella sindorme di Barter. Giornate endocrinologiche pisane 23–24 Nov., 1979.Google Scholar
  6. 6.
    Gullner HG, Cerletti C, Bartter FC, et al: Prostacyclin overproduction in Bartter’s syndrome. Lancet Oct 13, 767–769, 1979.CrossRefGoogle Scholar
  7. 7.
    Malmsten C: Prostaglandins, thromboxanes and platelets. Br J Haematol 41: 453–458, 1979.PubMedCrossRefGoogle Scholar
  8. 8.
    Tateson JE, Moncada S, Vane JR: Effects of prostacyclin on cAMP concentration in human platelets. Prostaglandins 13 (3): 389–397, 1977.PubMedCrossRefGoogle Scholar
  9. 9.
    Moncada S, Herman AG, Higgs EA, et al: Differential formation of prostacyclin by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium. Throm Res 11: 323–344, 1977.CrossRefGoogle Scholar
  10. 10.
    Stoff JS, Stemerman M, Steer M, et al: A defect in platelet aggregation in Bartter’s syndrome. Am J Med 68: 171–180, 1980.PubMedCrossRefGoogle Scholar
  11. 11.
    Lechi A, Mantero F, Opocher G, et al: Effect of indomethacin on urinary kallikrein excretion in Barter’s syndrome of the adult. J Endocrinol Invest 4: 17–20, 1981.PubMedGoogle Scholar
  12. 12.
    Girolami A, Randi M, Casonato A, et al: A study of platelet function and morphology in a new family with May-Hegglin anomaly. Folia Haematol 107: 256–268, 1980.Google Scholar
  13. 13.
    David JL, Herion F: Method for the measurement of C 14–5HT uptake and release by platelet function and thrombosis, in Mannucci PM, Gorini S (eds): A review of methods. New York, Plenum Press, 1972, pp 335–339.Google Scholar
  14. 14.
    Smith JB, Ingerman CM, Silver MG: Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 88: 167–172, 1976.PubMedGoogle Scholar
  15. 15.
    Gilman AG: A protein binding assay for adenosine 3’,5’-cyclic monophosphate. Proc Nat Acad Sci USA 67: 305–314, 1970.PubMedCrossRefGoogle Scholar
  16. 16.
    Salzman EW: Cyclic AMP and platelet function. N Engl J Med 17: 358–363, 1972.Google Scholar
  17. 17.
    Chan MK, Varghese Z, Moorhead JF: Urinary chloride excretion in suspected Bartter’s syndrome. N Engl J Med 301: 1450, 1979.PubMedGoogle Scholar
  18. 18.
    Gill JR, Bartter FC: Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter’s syndrome. Am J Med 65: 766–772, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Reznik V, Griswold WR, Mendoza SA: Neo-Mull-Soy metabolic alkalosis: a model for Bartter’s syndrome? Pediatrics 66 (5): 784–786, 1980.PubMedGoogle Scholar
  20. 20.
    Galvez OG, Bay WH, Roberts BW, et al: The hemodynamic effects of potassium deficiency in the dog. Circ Res Suppl 40: 11–16, 1977.Google Scholar
  21. 21.
    Dray F: Bartter’s syndrome: Contrasting patterns of prostaglandin excretion in children and adults. Clin Sci Mol Med 58: 115–118, 1978.Google Scholar
  22. 22.
    Gullner HG, Cerletti C, Barter FC, et al: Correction of increased prostacyclin synthesis by indomethacin treatment. Prost Med 4: 65–72, 1980CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • F. Fabris
    • 1
  • G. Opocher
    • 1
  • A. Casonato
    • 1
  • M. Randi
    • 1
  • A. Girolami
    • 1
  • F. Mantero
    • 1
  1. 1.Institute of Semeiotica MedicaUniversity of Padova Medical SchoolPadovaItaly

Personalised recommendations